Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™,

(Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate. The …, (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate. The …, Read More

Scroll to Top